Delving into the Latest Updates on VR-506 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

AsthmaPersistent asthma

Originator Organization

Vectura Group Ltd.

Active Organization-

Inactive Organization

Vectura Group Ltd.Vectura Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily regimen from a new dry powder inhaler (nDPI) for 16 weeks in subjects with severe persistent asthma requiring OCS therapy, i.e. Step 5 treatment as defined by modified Global Initiative for Asthma (GINA) guidelines 2011.

Start Date01 Oct 2012

Sponsor / Collaborator

Vectura Group Ltd.

EUCTR2011-001772-19-PL / Not yet recruitingNot Applicable

A randomised, double-blind, placebo controlled, parallel group, study to evaluate the efficacy and safety of VR506 inhalation powder from a new dry powder inhaler in adolescent and adult subjects with asthma. - Clinical study to evaluate the use of a new VR506 inhaler to treat Asthma

Start Date29 Nov 2011

Sponsor / Collaborator

Vectura Group Ltd.

NCT01472757 / CompletedPhase 2/3

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma

The purpose of the study is to evaluate the clinical efficacy of three doses of VR506 delivered via a new dry powder inhaler for the treatment of asthma.

Start Date01 Oct 2011

Sponsor / Collaborator

Vectura Group Ltd.

100 Clinical Results associated with VR-506

Login to view more data

100 Translational Medicine associated with VR-506

Login to view more data

100 Patents (Medical) associated with VR-506

Login to view more data

100 Deals associated with VR-506

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Persistent asthma	Phase 3	US	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	BG	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	DE	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	HU	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	PL	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	RO	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	UA	Vectura Group Ltd.	01 Oct 2012
Persistent asthma	Phase 3	GB	Vectura Group Ltd.	01 Oct 2012
Asthma	Phase 3	US	Vectura Ltd.	01 Oct 2011
Asthma	Phase 3	PH	Vectura Ltd.	01 Oct 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01472757 (CTgov)	Phase 2/3	Asthma	374	Placebo	hwmdaqstyv(tvcodwxrwk) = zisibjddmb jvpfryvmhv (ykbjdtpcjb, iwftbpkfdn - pshjaqajob) View more	-	21 Apr 2020
NCT01720069 (CTgov)	Phase 2/3	Persistent asthma	197	VR506 (Dose 1 VR506 50 mcg)	vhcidzfrml(afuufysrtu) = zwwuebvjqq rsaxajkesw (jpjgxupqkd, anselgajzd - lzrvoanyuz) View more	-	21 Apr 2020
NCT01720069 (CTgov)	Phase 2/3	Persistent asthma	197	VR506 (Dose 2 VR506 250 mcg)	vhcidzfrml(afuufysrtu) = jhyurwptyq rsaxajkesw (jpjgxupqkd, whqueggslg - vuplzpqnmo) View more	-	21 Apr 2020